Bristol-Myers Squibb Company (BMY) to Present New Investigational Data on Orencia® (abatacept) at the 2012 American College of Rheumatology Annual Scientific Meeting  
11/8/2012 10:33:24 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that new data from company-sponsored studies on Orencia SC in patients with rheumatoid arthritis (RA) and Orencia IV in juvenile idiopathic arthritis (JIA) will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Washington, D.C., November 10-14. Data from the company-sponsored studies will include new results from the AMPLE study examining changes in patient reported outcomes (PROs), including patient pain, patient global assessment and fatigue, and measures of remission. AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis Subjects With Background Methotrexate) is a head-to-head Phase III non-inferiority clinical trial comparing subcutaneous (SC) Orencia to Humira® (adalimumab), each on a background of methotrexate. Additionally, investigator sponsored research, supported by BMS, studying Orencia IV in mild relapsing granulomatosis with polyangiitis (Wegener’s) will be presented.